Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01956370
Other study ID # MRCZ/A/1628 Comparative study
Secondary ID
Status Completed
Phase Phase 2
First received September 19, 2012
Last updated October 6, 2013
Start date November 2011
Est. completion date February 2012

Study information

Verified date October 2013
Source Ministry of Health and Child Welfare, Zimbabwe
Contact n/a
Is FDA regulated No
Health authority Zimbabwe: Medical Research Council
Study type Interventional

Clinical Trial Summary

The protocol, approved by the Medical Research Council, was issued to assess the safety and efficacy of the non-surgical device for applying it to the national scale up of adult male circumcision in Zimbabwe


Description:

Models show that to have the highest impact on the HIV epidemic, circumcision of up to 80% of men in high prevalence countries, where MC rates are low, needs to be achieved (UNAIDS 2009; Manicaland HIV/STD Prevention Project, 2008; Bollinger, et al, 2009). Hallett and colleagues in 2008 showed that for Zimbabwe specifically, HIV incidence could be reduced between 25% to 35% if about 50% of men are circumcised. All modelings conducted show that MC programs must be part of a comprehensive HIV prevention package as MC alone will not tip the HIV epidemic into a terminal decline.

The PrePex Device offers hope for rapid scale up of adult male circumcision in resource limited settings.

Once the safety and efficacy have been established, it is important to conduct operations research to determine how best to implement both device and surgical circumcisions in the national program. Thus, the Zimbabwe MOHCW is planning a three phase trial in order to determine the safety of the PrePexTM device, its performance and the ease of use in an implementation roll out.


Recruitment information / eligibility

Status Completed
Enrollment 240
Est. completion date February 2012
Est. primary completion date February 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria:

- Ages 18 - 30 years

- Uncircumcised

- Wants to be circumcised

- Agrees to be circumcised by any of the study methods,PrePexTM or Surgical as appropriate

- HIV sero-negative

- Able to understand the study procedures and requirements

- Agrees to abstain from sexual intercourse and to keep caution not to directly rub the cut area if masturbating, for 8 weeks post removal (9 weeks total)

- Agrees to return to the health care facility for follow-up visits (or as instructed) after his circumcision for a period of 8 weeks post removal (9 weeks total)

- Subject able to comprehend and freely give informed consent for participation in this study and is considered by the investigator to have good compliance for the study

- Subject agrees to anonymous video and photographs of the procedure and follow up visits

- Agrees to stay overnight at the Hospital in order to follow pain measurements in the first 16 hours

Exclusion Criteria:

- Active genital infection, anatomic abnormality or other condition, which in the opinion of the investigator prevents the subject from undergoing a circumcision

- HIV sero-positive

- Subject with the following diseases/conditions: phimosis, paraphimosis, warts under the prepuce, torn or tight frenulum, narrow prepuce, hypospadias, epispadias

- Known bleeding / coagulation abnormality

- Uncontrolled diabetes

- Subject that to the opinion of the investigator is not a good candidate

- Subject does not agree to anonymous video and photographs of the procedure and follow up visits

- Refusal to take HIV test.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Device:
PrePex™ device for adult male circumcision
The PrePex™ device is designed to enable bloodless male circumcision procedure with no anesthesia and no sutures.
Procedure:
Surgical circumcision
The penis will be surgically circumcised according to one of the WHO recommended circumcision methods as described in the Manual for Male Circumcision under Local Anaesthesia Version 2.5C January 2008

Locations

Country Name City State
Zimbabwe Znfpc Spilhaus Center Harare

Sponsors (1)

Lead Sponsor Collaborator
Ministry of Health and Child Welfare, Zimbabwe

Country where clinical trial is conducted

Zimbabwe, 

Outcome

Type Measure Description Time frame Safety issue
Primary Procedure time To compare the total operative time of the PrePex Device circumcision procedure versus the total operative time of surgical circumcision procedure. 9 weeks No
Secondary Expectations of men regarding the procedure Expectations of men regarding the procedure using questionnaires 9 weeks No
Secondary Satisfaction rate of the procedure Satisfaction with procedure using questionnaires and evaluations 9 weeks No
Secondary Attitudes towards procedure Attitudes towards procedure using questionnaires 9 weeks No
Secondary Sharing information with family and friends Sharing information with family and friends by evaluating weather subjects would recommend the procedure to others using questionnaires 9 weeks No
Secondary Perception of norms Perception of norms using questionnaires 9 weeks No
Secondary Sexual relations, performance, satisfaction Sexual relations, performance, satisfaction using questionnaires 9 weeks No
Secondary Sexual behavior Sexual behavior using questionnaires. Inquiring of sexual behavior before and after the circumcision, etc. 9 weeks No
Secondary Sexual partner's attitudes Sexual partner's attitudes using questionnaires and investigating the partner's behavior change as a result of her partner's circumcision. 9 weeks No
Secondary Effect on daily activities Effect on daily activities using questionnaires. Inquiring and finding out if the MC procedure caused any missing of working days. 9 weeks No
Secondary Costs Evaluating the cost of PrePex circumcision procedure when taking into account the following parameters:
i. PrePex Procedure time and the resulting cost of provider's time ii. Cost of staff time for follow-up visits iii. Cost of equipment and supplies needed for the circumcision procedure
9 weeks No
Secondary Cost-effectiveness Cost-effectiveness 9 weeks No
See also
  Status Clinical Trial Phase
Recruiting NCT06162897 - Case Management Dyad N/A
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT02528773 - Efficacy of ART to Interrupt HIV Transmission Networks
Active, not recruiting NCT05454839 - Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
Recruiting NCT05322629 - Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women N/A
Completed NCT02579135 - Reducing HIV Risk Among Adolescents: Evaluating Project HEART N/A
Active, not recruiting NCT01790373 - Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence N/A
Not yet recruiting NCT06044792 - The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
Completed NCT04039217 - Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM Phase 4
Active, not recruiting NCT04519970 - Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK) N/A
Completed NCT04124536 - Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women N/A
Recruiting NCT05599581 - Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health N/A
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Completed NCT02758093 - Speed of Processing Training in Adults With HIV N/A
Completed NCT02500446 - Dolutegravir Impact on Residual Replication Phase 4
Completed NCT03805451 - Life Steps for PrEP for Youth N/A
Active, not recruiting NCT03902431 - Translating the ABCS Into HIV Care N/A
Completed NCT00729391 - Women-Focused HIV Prevention in the Western Cape Phase 2/Phase 3
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2

External Links